ANDAINJECTIONINJECTABLE
Approved
Dec 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ISOPROTERENOL HYDROCHLORIDE (isoproterenol hydrochloride) by Deva Holdings is beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors. First approved in 2025.
Drug data last refreshed 21h ago
Mechanism of Action
beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on ISOPROTERENOL HYDROCHLORIDE at Deva Holdings? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.